Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812325 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease (TED), sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT06812325: Active Phase 3 study of Thyroid Eye Disease (TED), sponsored by Viridian Therapeutics.
NCT06812325 is a Phase 3 study of Thyroid Eye Disease (TED) that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 321 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06812325, a Phase 3 study of Thyroid Eye Disease (TED), is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Primary Outcome
Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRDN-003
Study Locations (20)
Florida
- C A Clinical Trial Corp. - Cape Coral
- Herco Medical and Research Center - Coral Gables
- Alfa Medical Research - Davie
- D H Doral Research Center - Doral
- Eye Centers of Florida - Fort Myers
- Sina Medical Center - Homestead
- East Coast Institute for Research, LLC - Jacksonville
- Southern Clinical Research LLC - Miami
- Retreat Medical Research - Miami
- Continental Clinical Research - Miami
- Edward Jenner Research Group LLC - Plantation
- Sarasota Retina Institute - Sarasota
California
- United Medical Research Institute - Inglewood
- Orbital Plastics - Newport Beach
- California Eye Specialists Medical Group INC - Pasadena
- FOMAT Medical Research - Pismo Beach
- Pacific Neuroscience Institute - Santa Monica
- Pacific Neuroscience Institute at Saint John's Physician Partners - Torrance
Arizona
- Catalina Eye Care - Tuscon
Illinois
- Advanced Quality Medical Research - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
What the registry record for NCT06812325 still lists
NCT06812325 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Thyroid Eye Disease (TED) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06812325 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06812325 about?
NCT06812325 is a clinical study titled "A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
What is the current status of trial NCT06812325?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2025-02-03. Estimated completion is 2026-10.
What conditions does trial NCT06812325 study?
This clinical trial studies the following conditions: Thyroid Eye Disease (TED).
What interventions are being tested in trial NCT06812325?
The interventions under investigation include: Placebo (DRUG), VRDN-003 (DRUG).
Who is sponsoring clinical trial NCT06812325?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812325 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06812325's enrollment target sits among peer trials
321 1082nd of 2000 higher than 919 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI